News for Acumen Pharmaceuticals, Inc. (ABOS)

Cash and Marketable Securities: $197.9 million as of March 31, 2025.R&D Expenses: $25.3 million in Q1 2025.G&A Expenses: $5.1 million in Q1 2025.Loss from Oper

May 13, 2025 / 12:00PM GMTOperator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 conference call and webcast. At this ti

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsAlex Braun - Head, Investor...

**media[618079]**

PR NewswireSAN DIEGO, May 6, 2025 Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39%

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. ( ABOS) (”œAcumen” or the ”œCompany”), a clinical-stage biopharmaceutical c

PR NewswireSAN DIEGO, May 5, 2025 SAN DIEGO, May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. H

PR NewswireSAN DIEGO, April 28, 2025 SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it w

PR NewswireSAN DIEGO, April 28, 2025 European Commission (EC) decision on marketing authorization application expected within approximately two monthsSAN D

PR NewswireSAN DIEGO, April 9, 2025 Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technologySAN DIEGO, April 9, 2025 /PR

**media[583666]**

**media[582591]**

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Cash and Marketable Securities: $231.5 million as of the end of 2024.R&D Expenses: $93.8 million in 2024, increased due to ALTITUDE-AD trial support.G&A Expens

Discover Acumen Pharmaceuticals' progress on Alzheimer's treatment sabirnetug, Phase 2 trial updates, biomarker advancements, and financial strategies.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ETCompany ParticipantsAlex Braun - Head, Investor...

NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. ( ABOS) (”œAcumen” or the ”œCompany”), a clinical-stage biopharmaceutical

Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration supports furthe

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals ( ABOS) CEO Danie